Home » Stocks » ECOR

electroCore, Inc. (ECOR)

Stock Price: $1.01 USD -0.01 (-0.98%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 69.94M
Revenue (ttm) 3.97M
Net Income (ttm) -20.94M
Shares Out 47.65M
EPS (ttm) -0.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $1.01
Previous Close $1.02
Change ($) -0.01
Change (%) -0.98%
Day's Open 1.00
Day's Range 1.00 - 1.02
Day's Volume 2,162,781
52-Week Range 0.99 - 3.63

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

ROCKAWAY, NJ, July 19, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its cofounder and Chief Medical...

6 days ago - GlobeNewsWire

ROCKAWAY, NJ, July 09, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Dan Goldberger, CEO will present a company overv...

2 weeks ago - GlobeNewsWire

ElectroCore Inc (NASDAQ: ECOR) has priced underwritten public offering of 18 million shares at $1 per share, representing a discount of 32% from the last close price of $1.48 on Tuesday. The gross proce...

3 weeks ago - Benzinga

ROCKAWAY, NJ, June 30, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced the pricing of an underwritten publi...

3 weeks ago - GlobeNewsWire

ROCKAWAY, NJ, June 29, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that it intends to offer and sell sha...

3 weeks ago - GlobeNewsWire

ROCKAWAY, NJ, June 24, 2021 (GLOBE NEWSWIRE) --  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper on June 10,...

1 month ago - GlobeNewsWire

ROCKAWAY, NJ, June 09, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has completed the sale of $1.4 million of its...

1 month ago - GlobeNewsWire

ROCKAWAY, N.J., June 02, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper, entitled ...

1 month ago - GlobeNewsWire

ROCKAWAY, NJ, May 26, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced today that its management team will present a several invest...

1 month ago - GlobeNewsWire

ROCKAWAY, N.J.--(BUSINESS WIRE)--National Military Appreciation Month commemorates and expresses gratitude for the sacrifices current and former members of the U.S. armed forces have made for our countr...

2 months ago - Business Wire

ROCKAWAY, N.J.--(BUSINESS WIRE)--electroCore, Inc., a commercial-stage bioelectronic medicine company, commends the results of the VNS-REHAB study published in the April 24th edition of The Lancet which...

2 months ago - Business Wire

Record First quarter 2021 net sales of $1.2 million, increased 64% over first quarter 2020 and 30% sequentially

2 months ago - GlobeNewsWire

ROCKAWAY, NJ, April 29, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the first quarte...

2 months ago - GlobeNewsWire

ROCKAWAY, NJ, April 26, 2021 (GLOBE NEWSWIRE) --  -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Johns Hopkins University School of Medicine...

2 months ago - GlobeNewsWire

ROCKAWAY, NJ, April 15, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a paper, entitled, “Cluster heada...

3 months ago - GlobeNewsWire

ROCKAWAY, NJ, April 13, 2021 (GLOBE NEWSWIRE) --  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an operating and business update as well as select u...

3 months ago - GlobeNewsWire

ElectroCore Inc (NASDAQ: ECOR) has announced top-line results from the SAVIOR-1 study evaluating non-invasive vagus nerve stimulation (nVNS) using gammaCore Sapphire in hospitalized COVID-19 patients. T...

3 months ago - Benzinga

nVNS decreases certain biomarkers associated with the severity of COVID-19 through five days of treatment nVNS decreases certain biomarkers associated with the severity of COVID-19 through five days of ...

3 months ago - GlobeNewsWire

Health Canada has approved ElectroCore Inc's (NASDAQ: ECOR) gammaCore Sapphire family of products to prevent and treat migraine and cluster headache. GammaCore Sapphire will be distributed in Canada by ...

3 months ago - Benzinga

ROCKAWAY, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that Health Canada has granted regulatory approval f...

3 months ago - GlobeNewsWire

ROCKAWAY, N.J.--(BUSINESS WIRE)--Amid the vaccine roll out, 97,309 new cases of COVID-19 have been reported to the CDC. Peter Staats, M.D. Chief Medical Officer of electroCore, Inc. (Nasdaq: ECOR), outl...

4 months ago - Business Wire

Full year 2020 net sales of approximately $3.5 million increased 46% over $2.4 million for full year 2019

4 months ago - GlobeNewsWire

ROCKAWAY, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management will participate in two upcoming i...

4 months ago - GlobeNewsWire

Shares of electroCore, Inc. (NASDAQ: ECOR) were trading higher Monday following the company's announcement of an exclusive distribution agreement with Medistar following regulatory approval in Australia...

4 months ago - Benzinga

ElectroCore (ECOR) stock is rocketing higher on Monday after announcing a distribution deal in Australia for its gammaCore Sapphire. The post ECOR Stock: The Deal That Has Medical Device Company Electro...

4 months ago - InvestorPlace

The Australian Therapeutic Goods Administration has approved ElectroCore Inc's (NASDAQ: ECOR) gammaCore Sapphire family of products, including a non-invasive vagus nerve stimulator (nVNS) for primary he...

4 months ago - Benzinga

ROCKAWAY, N.J., Feb. 28, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement with Medistar...

4 months ago - GlobeNewsWire

ElectroCore Inc (NASDAQ: ECOR) and the Hospital Clínico Universitario de Valencia in Spain have completed the enrollment in the SAVIOR-1 study. This study was supported in part by electroCore.

5 months ago - Benzinga

ROCKAWAY, N.J.--(BUSINESS WIRE)--electroCore,Inc.(Nasdaq: ECOR) closes patient enrollment study SAVIOR-1 to better understand clinical benefit of non-invasive vagus nerve stimulation

5 months ago - Business Wire

Extension maintains listing through June 3, 2023 Extension maintains listing through June 3, 2023

5 months ago - GlobeNewsWire

FDA clearance expands gammaCore label to include the acute and preventive treatment of migraine in adolescents 12 to 17 years of age FDA clearance expands gammaCore label to include the acute and preven...

5 months ago - GlobeNewsWire

ROCKAWAY, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed paper, entitled:...

5 months ago - GlobeNewsWire

ROCKAWAY, N.J., Feb. 03, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management will participate in a fireside chat...

5 months ago - GlobeNewsWire

ROCKAWAY, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that full enrollment has been achieved for the TR-V...

5 months ago - GlobeNewsWire

ROCKAWAY, N.J., Jan. 26, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement with RSK Medi...

5 months ago - GlobeNewsWire

ROCKAWAY, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Health Improvement Scotland (“HIS”) has publis...

6 months ago - GlobeNewsWire

ROCKAWAY, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Centers for Medicare and Medicaid Services (“C...

6 months ago - GlobeNewsWire

Full year 2020 revenue expected at the upper end of previously announced guidance range of $3.3M - $3.5M; greater than 40% growth over full year 2019 revenue of $2.4M

6 months ago - GlobeNewsWire

ROCKAWAY, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement with Pro Medi...

7 months ago - GlobeNewsWire

BASKING RIDGE, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management is scheduled to present at the...

7 months ago - GlobeNewsWire

electroCore's (ECOR) CEO Dan Goldberger on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Shares of electroCore (NASDAQ:ECOR) moved higher by 10.83% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 71.43% over the past year to ($0.10...

8 months ago - Benzinga

On Thursday, November 12, electroCore (NASDAQ: ECOR) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.

8 months ago - Benzinga

Conference Call to be Held at 4:30pm Eastern Time Conference Call to be Held at 4:30pm Eastern Time

8 months ago - GlobeNewsWire

Third quarter 2020 Revenue expected to exceed $1 million , representing an increase of greater than 35% sequentially and greater than 50% over Q3 2019

9 months ago - GlobeNewsWire

ITP program providing reimbursement for gammaCore ™ extended to March. 31, 2021 with option for additional three years

9 months ago - GlobeNewsWire

BASKING RIDGE, N.J., Sept. 30, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the Department of Veterans Affairs has a...

9 months ago - GlobeNewsWire

Comprehensive telehealth platform to facilitate the efficient procurement of gammaCore Sapphire™ CV (non-invasive vagus nerve stimulator) by known or suspected COVID-19 patients Comprehensive telehealth...

10 months ago - GlobeNewsWire

BASKING RIDGE, N.J., Sept. 23, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Dan Goldberger, chief executive office...

10 months ago - GlobeNewsWire

BASKING RIDGE, N.J., Sept. 11, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that management is scheduled to present at ...

10 months ago - GlobeNewsWire

About ECOR

electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in R... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
Jun 22, 2018
CEO
Francis Amato
Employees
45
Stock Exchange
NASDAQ
Ticker Symbol
ECOR
Full Company Profile

Financial Performance

In 2020, electroCore's revenue was $3.50 million, an increase of 46.25% compared to the previous year's $2.39 million. Losses were -$23.51 million, -47.92% less than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for electroCore stock is "Buy." The 12-month stock price forecast is 3.60, which is an increase of 256.44% from the latest price.

Price Target
$3.60
(256.44% upside)
Analyst Consensus: Buy